T-Cell Lymphoma Clinical Trial
Official title:
Real-World Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma Patients
Verified date | March 2024 |
Source | Takeda |
Contact | Takeda Contact |
Phone | +1-877-825-3327 |
medinfoUS[@]takeda.com | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The main aim of this study is to describe how effective and safe the re-treatment of adults with cutaneous T-cell lymphoma (CTCL) with brentuximab vedotin is. Another aim is to describe treatment patterns of persons with CTCL who have received brentuximab vedotin again. No treatment will be provided during this study. Information already existing in the participants' medical charts will be reviewed and collected.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | June 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Participant with a confirmed diagnosis of CTCL (including Mycosis fungoides (MF), Sézary syndrome (SS), Primary cutaneous CD30+ anaplastic large cell lymphoma (pcALCL) and others) who reached a complete response (CR), partial response (PR) or stable disease (SD) on a previous treatment with BV and whose disease relapsed - Participant who was treated with BV in at least 2 lines of therapy, other treatments could have been administered in between - Participant has received three or more cycles of BV in retreatment Exclusion criteria: There are no exclusion criteria for this study. |
Country | Name | City | State |
---|---|---|---|
France | Hopital Saint Andre | Bordeaux | |
France | Hopital Saint Louis | Paris | |
France | CHU Roeun | Rouen | |
Germany | Universitätsmedizin Göttingen | Göttingen | |
Germany | Klinikum Ludwigshafen, Hautklinik | Ludwigshafen | |
Germany | Universitätsklinikum Würzburg | Würzburg | |
Italy | Ospedale Maggiore Policlinico | Milan | |
Italy | AZ OSP Citta' Della Salute (Torino) | Torino | |
Spain | Hospital Clinic, Barcelona | Barcelona | |
Spain | ICO Hospitalet, Barcelona | Barcelona | |
Spain | Hospital Son Espases | Palma |
Lead Sponsor | Collaborator |
---|---|
Takeda |
France, Germany, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) After First BV Administration | Up to approximately 12 months | ||
Primary | ORR After Re-Treatment | Up to approximately 12 months after BV retreatment | ||
Primary | Progression Free Survival (PFS) After First BV Administration | Up to approximately 24 months | ||
Primary | PFS After BV Re-Treatment | Up to approximately 24 months after BV retreatment | ||
Primary | Time to Next Treatment (TTNT) After First BV Administration (Regardless of Type of Next Treatment, i.e., BV or non-BV) | Up to approximately 16 months | ||
Primary | TTNT After BV Re-Treatment | Up to approximately 24 months after BV retreatment | ||
Primary | Number of Participant With Grading of Motor Neuropathy During First BV Treatment | Up to approximately 12 months | ||
Primary | Time to Improvement of Motor Neuropathy During/ Post First BV Treatment | Up to approximately 24 months | ||
Primary | Time to Resolution of Motor Neuropathy During/ Post First BV Treatment | Up to approximately 24 months | ||
Primary | Number of Participants With Grading of Motor Neuropathy During BV Re-Treatment | Up to approximately 12 months after BV retreatment | ||
Primary | Time to Improvement of Motor Neuropathy During/ Post BV Re-Treatment | Up to approximately 16 months | ||
Primary | Time to Resolution of Motor Neuropathy During/ Post BV Re-Treatment | Up to approximately 24 months | ||
Primary | Number of Participants With Grading of Sensory Neuropathy During First BV Treatment | Up to approximately 12 months | ||
Primary | Time to Improvement of Sensory Neuropathy During/ Post First BV Treatment | Up to approximately 24 months | ||
Primary | Time to Resolution of Sensory Neuropathy During/ Post First BV Treatment | Up to approximately 24 months | ||
Primary | Number of Participants With Grading of Sensory Neuropathy During BV Re-Treatment | Up to approximately 12 months | ||
Primary | Time to Improvement of Sensory Neuropathy During/ Post BV Re-Treatment | Up to approximately 24 months | ||
Primary | Time to Resolution of Sensory Neuropathy During/ Post BV Re-Treatment | Up to approximately 24 months | ||
Primary | Number of Participants With Grading of Neutropenia During First BV Treatment | Up to approximately 12 months | ||
Primary | Number of Participants With Grading of Neutropenia During BV Re-Treatment | Up to approximately 12 months | ||
Primary | Number of Participants With Grading of Febrile Neutropenia During First BV Treatment | Up to approximately 24 months | ||
Primary | Number of Participants With Grading of Febrile Neutropenia During BV Re-Treatment | Up to approximately 12 months | ||
Primary | Number of Participants With Grading of Serious Infections During First BV Treatment | Up to approximately 12 months | ||
Primary | Number of Participants With Grading of Serious Infections During BV Re-Treatment | Up to approximately 12 months | ||
Secondary | Number of Participants With Cutaneous Lymphoma Co-Medications or Strategies Used to Treat CTCL Disease | Up to approximately 12 months | ||
Secondary | Amount of BV Dose | Up to approximately 12 months | ||
Secondary | Number of Cycles of BV Administered | Up to approximately 12 months | ||
Secondary | Time Interval Between BV Administration | Up to approximately 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00959686 -
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04712864 -
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01941680 -
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
|
||
Recruiting |
NCT05075460 -
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
|
Phase 3 | |
Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT02017613 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT01854112 -
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
|
N/A | |
Completed |
NCT01553786 -
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
|
Phase 2 | |
Completed |
NCT00542919 -
A Study for Patients With Non-Hodgkin's Lymphomas
|
Phase 2 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Active, not recruiting |
NCT03952078 -
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT05387226 -
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
|
Phase 1 | |
Completed |
NCT02424045 -
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
Completed |
NCT01871675 -
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT00893516 -
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
|
Phase 2 | |
Completed |
NCT01902225 -
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT02086591 -
A Phase II Study of Doxycycline in Relapsed NHL
|
Phase 2 | |
Recruiting |
NCT04264078 -
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
|
Early Phase 1 | |
Completed |
NCT00001582 -
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
|